82
Participants
Start Date
September 1, 2016
Primary Completion Date
September 17, 2019
Study Completion Date
October 24, 2019
ARRY-382
ARRAY-382 will be taken by mouth once daily at a fixed dose.
Pembrolizumab
Pembrolizumab will be administered intravenously over 30 minutes every 3 weeks.
University of Virginia Cancer Center, Charlottesville
UVA Health System, Charlottesville
Hem-Onc Associates of Treasure Coast, Port Saint Lucie
Tennessee Oncology PLLC, Nashville
Tennessee Oncology, PLLC, Nashville
The Sarah Cannon Research Institute, Nashville
Parkview Cancer Institute, Fort Wayne
Parkview Regional Medical Center, Fort Wayne
Parkview Research Center, Fort Wayne
PPG, Fort Wayne
Horizon Oncology Research, Inc., Lafayette
Karmanos Cancer Institute, Detroit
Hall-Perrine Cancer Center Laboratory, Cedar Rapids
Regions Cancer Care Center, Saint Paul
Regions Hospital Pharmacy, Saint Paul
Regions Hospital, Saint Paul
HealthPartners Neurosciences Center, Saint Paul
Mayo Clinic Labs - Rochester Superior, Rochester
UT Health Cancer Center, San Antonio
University of Colorado Denver, Aurora
University of Colorado Hospital, Aurora
UTAH Cancer Specialists, Salt Lake City
Ronald Reagan UCLA Medical Center, Los Angeles
UCLA Hematology/Oncology, Los Angeles
UCLA Hematology/Oncology - Santa Monica, Santa Monica
Massachusetts General Hospital, Boston
Brigham and Women's Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston
ARUP Laboratories, Inc., Salt Lake City
Lead Sponsor
Pfizer
INDUSTRY